Patents Assigned to Emory University
  • ANNULOPLASTY RINGS AND METHODS FOR HEART VALVE REPAIR
    Publication number: 20130030523
    Abstract: An annuloplasty ring, configured for implantation in the annulus of a heart valve, comprising multiple segments each of which are geometrically shaped from a three dimensional perspective to conform to the anatomic shape of the valve annulus. In one embodiment, the annuloplasty ring is configured to facilitate a reduction of tension on heart valve tissue and eliminate a substantial portion of potential pressure or force that may be applied to the atrioventricular node by the annuloplasty ring when implanted. In another embodiment, at the annuloplasty ring is configured to include an assembly that facilitates selective adjustment of a segment's respective length and/or shape. The adjustment of the length of one of the ring segment's results in an adjustment of at least one angle between at least one set of other ring segments, thereby causing an adjustment to the geometric characteristics of the ring.
    Type: Application
    Filed: April 7, 2009
    Publication date: January 31, 2013
    Applicants: Emory University, Georgia Tech Research Corporation
    Inventors: Sai Muralidhar Padala, Ajit P. Yoganathan, Vinod H. Thourani, Jorge H. Jimenez
  • Modified Factor VIII
    Publication number: 20130005656
    Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.
    Type: Application
    Filed: March 27, 2012
    Publication date: January 3, 2013
    Applicant: Emory University
    Inventor: John S. Lollar
  • CANCER BIOMARKERS TO PREDICT RECURRENCE AND METASTATIC POTENTIAL
    Publication number: 20130005837
    Abstract: Described herein are methods for predicting recurrence, progression, and metastatic potential of a prostate cancer in a subject. In certain embodiments, the methods comprise analyzing a sample from a subject for aberrant expression patters of one or more biomarkers disclosed herein. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.
    Type: Application
    Filed: December 29, 2010
    Publication date: January 3, 2013
    Applicant: Emory University
    Inventors: Carlos Moreno, Qi Long, Benjamin G. Barwick
  • Catheter for modified perfusion
    Patent number: 8343131
    Abstract: A catheter adapted for use in passing fluids and medicines therethrough for use in the perfusion or reperfusion of blood or blood-fluid mixtures into the arteries, veins, tissues, conduits, or organs of a patient by selectively adjusting the flow rate of fluid supplied to a drug delivery lumen of the catheter based at least in part on the sensed systemic fluid pressure and the sensed fluid pressure at a distal end of the catheter is disclosed.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: January 1, 2013
    Assignee: Emory University
    Inventor: Jakob Vinten-Johansen
  • BIODEGRADABLE POLYMERIC NETWORKS AND METHODS FOR MANUFACTURING THE SAME
    Publication number: 20120322895
    Abstract: Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1.
    Type: Application
    Filed: February 23, 2011
    Publication date: December 20, 2012
    Applicants: Emory University, Georgia Tech Research Corporation
    Inventors: David Safranski, Kenneth Gall, W. Robert Taylor, Daiana Weiss
  • Method of Administering Porcine B-Domainless fVIII
    Publication number: 20120270788
    Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.
    Type: Application
    Filed: January 23, 2012
    Publication date: October 25, 2012
    Applicant: Emory University
    Inventors: John S. Lollar, Garrett E. Bergman
  • Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
    Patent number: 8268809
    Abstract: The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: September 18, 2012
    Assignees: Emory University, M.D. Anderson Cancer Center
    Inventors: Daniel Kalman, William Bornmann
  • METHODS AND DEVICES FOR DRUG DELIVERY TO OCULAR TISSUE USING MICRONEEDLE
    Publication number: 20120226260
    Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
    Type: Application
    Filed: April 15, 2012
    Publication date: September 6, 2012
    Applicants: Georgia Tech Research Corporation, Emory University
    Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
  • Strategies for delivery of active agents using micelles and particles
    Patent number: 8252846
    Abstract: The present invention provides biodegradable particles (e.g., three-dimensional particles) and micelles which can be used to encapsulate active agents for delivering to a subject. The present invention further provides methods for producing and delivering such particles and micelles. Additionally, the invention provides vaccination strategies that encompass the use of the novel particles and micelles.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: August 28, 2012
    Assignees: Emory University, Georgia Tech Research Corporation, University of Rochester
    Inventors: Niren Murthy, Bali Pulendran, Robert H. Pierce, Michael John Heffernan, Jihua Hao, Marcin Kwissa, Michael Davis, Stephen C. Yang
  • Neurotrophic activity of deoxygedunin
    Patent number: 8203009
    Abstract: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or hetero-cycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders including neurologic, neuropsychiatric, and metabolic disorders are provided. For example, a method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of the described compounds.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: June 19, 2012
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Methods and devices for drug delivery to ocular tissue using microneedle
    Patent number: 8197435
    Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: June 12, 2012
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
  • MONOPHOSPHATE PRODRUGS OF DAPD AND ANALOGS THEREOF
    Publication number: 20120142627
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV and HBV, in human patients or other animal hosts. The compounds are certain 6-substituted-2-amino-purine dioxolane monophosphates or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof.
    Type: Application
    Filed: November 29, 2011
    Publication date: June 7, 2012
    Applicants: Emory University, RFS Pharma, LLC
    Inventors: Raymond F. Schinazi, Steven J. Coats
  • Triptolide analogs for the treatment of autoimmune and inflammatory disorders
    Patent number: 8193249
    Abstract: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: June 5, 2012
    Assignee: Emory University
    Inventors: Susheng Wang, Dennis C. Liotta, James P. Snyder, Hariharan Venkatesan
  • Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
    Patent number: 8193200
    Abstract: The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 5, 2012
    Assignees: University of Virginia Patent Foundation, Emory University
    Inventors: Shanthi V. Sitaraman, Joel M. Linden, Guoquan Wang, Robert Douglas Thompson, Jayson M. Rieger
  • 2-fluoronucleosides
    Patent number: 8168583
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: May 1, 2012
    Assignees: University of Georgia Research Foundation, Inc., Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Dual closing guide for a surgical instrument
    Patent number: 8147512
    Abstract: A hand-operated surgical instrument with sequentially engaged tip closing guides. The instrument includes first and second arms having tips that close during a closure operation. A slotted tip closure guide on the arms engages first during the closure operation. A pin closure guide on the arms between the slotted closure guide and the tips engages during the closure operation after the engagement of the slotted closure guide. The sequential engagement of the guides provides precise approximation of the instrument tips and prevents “scissoring” of the tips.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: April 3, 2012
    Assignees: Scanlan International, Inc., Emory University
    Inventors: John Puskas, Gaylord Kube
  • COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST
    Publication number: 20120071539
    Abstract: Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic compositions comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided.
    Type: Application
    Filed: December 12, 2007
    Publication date: March 22, 2012
    Applicant: Emory University
    Inventor: Peng Jin
  • NANOCARRIER THERAPY FOR TREATING INVASIVE TUMORS
    Publication number: 20120052115
    Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
    Type: Application
    Filed: April 21, 2010
    Publication date: March 1, 2012
    Applicants: Emory University, Georgia Tech Research Corporation
    Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
  • CXCR4 antagonists for the treatment of medical disorders
    Patent number: 8114884
    Abstract: The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: February 14, 2012
    Assignee: Emory University
    Inventors: Hyunsuk Shim, Dennis C. Liotta, James P. Snyder, Weiqiang Zhan, Zhongxing Liang
  • 2? and 3?-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation
    Patent number: 8114994
    Abstract: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: February 14, 2012
    Assignee: Emory University
    Inventors: Dennis C. Liotta, Shuli Mao, Michael Hager, Raymond F Schinazi